ND-340 is under clinical development by Nang Kuang Pharmaceutical and currently in Phase I for Post-Operative Pain. According to GlobalData, Phase I drugs for Post-Operative Pain have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ND-340’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ND-340 is under development for the treatment of post-operative analgesia in patients with total knee arthroplasty (TKA). It is an extended release formulation, administered through parenteral route as suspension.
Nang Kuang Pharmaceutical overview
Nang Kuang Pharmaceutical (Nang Kuang) is a pharmaceutical company that produces injectables. The company’s product includes large volume parenterals, lyophilized injection, aseptic parenterals, pre-filled syringe, tablets, capsules, topical products and oral suspensions. Its products are used in the therapeutic areas of cardiovascular, gastrointestinal, nervous system, blood, musculo-skeletal, respiratory, dermatology, genito-urinary and others. Nang Kuang carries out co-marketing arrangements with many pharmaceutical companies in the US and Europe. It offers various hospital solution including electrolyte solution, ringer lactate solution, sodium chloride solution, sterile water, carbohydrate and electrolyte solution, amino-acid solution and nephro amino-acid solution, among others. Nang Kuang is headquartered in Tainan, Taiwan.
For a complete picture of ND-340’s drug-specific PTSR and LoA scores, buy the report here.